Crispr Therapeutics AG ( (CRSP) ) has risen by 13.29%. Read on to learn why.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Crispr Therapeutics AG has seen a notable increase in its stock price, rising by 13.29% over the past week. This surge is largely attributed to a bullish option flow, with a significant number of call options being traded, indicating investor optimism. The company’s implied volatility has also increased, reflecting heightened interest and activity in the stock. Additionally, the Put/Call Ratio is at a low 0.14, further suggesting a positive sentiment among traders.
Several analysts have maintained or reiterated their positive outlook on Crispr Therapeutics AG, contributing to the stock’s upward momentum. Notably, William Blair analyst Sami Corwin has reiterated a Buy rating, highlighting the company’s promising future with the launch of Casgevy and its diversified pipeline in areas such as immuno-oncology and autoimmune diseases. The company’s strategic partnerships and anticipated milestones are seen as key drivers for its growth, supporting the bullish sentiment.
Moreover, influential investor Cathie Wood’s ARK Investment has significantly increased its stake in Crispr Therapeutics, purchasing a substantial number of shares. This move by a well-regarded investor has likely bolstered confidence in the stock, attracting more attention from the market. With earnings expected soon and a positive consensus among analysts, Crispr Therapeutics AG appears to be on a strong trajectory, capturing the interest of investors looking for opportunities in the biotechnology sector.